Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DA WEI LIAO

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1053379263
CMS profile
183971
Location
BETHESDA, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$57,188.89

157 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 4 of 4; records 151–157 of 157 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DA WEI LIAO

NPI 1053379263 · CMS profile ID 183971

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

BETHESDA, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–157 of 157 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053379263?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DA WEI LIAO, NPI 1053379263, CMS profile ID 183971. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–157 of 157 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053379263?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DA WEI LIAO, NPI 1053379263, CMS profile ID 183971. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–157 of 157 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053379263?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DA WEI LIAO, NPI 1053379263, CMS profile ID 183971, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–157 of 157 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1053379263?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

157 matching records · $57,188.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 157 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–157 of 157.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $11.7002/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843539715 CMS
GlaxoSmithKline, LLC. $10.4102/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803026295 CMS
PARI Respiratory Equipment, Inc. $14.9502/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838602773 CMS
AstraZeneca Pharmaceuticals LP $124.7501/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830107615 CMS
GlaxoSmithKline, LLC. $23.8001/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803195999 CMS
Nestle HealthCare Nutrition Inc. $900.0001/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820921939 CMS
GlaxoSmithKline, LLC. $10.4001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802543447 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,579.89 204
PY2020 $29,212.65 85
PY2021 $57,188.89 157
PY2022 $54,460.88 173
PY2023 $50,299.31 192
PY2024 $40,791.55 192
PY2025 $50,999.32 187

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $578,012.52 64
PY2024 Recipient $2,038.61 16
PY2024 Principal investigator $326,688.69 44
PY2023 Recipient $2,635.85 17
PY2023 Principal investigator $84,314.00 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $3,535.20 12/23/2025 Non-covered Recipient Entity
CLINIC RESEARCH
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192146197
Principal investigator 1 GENZYME CORPORATION $6,719.00 12/15/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125886
Principal investigator 1 SANOFI US SERVICES INC. $13,085.00 12/08/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226083530
Principal investigator 1 United Therapeutics Corporation $2,000.00 12/02/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387191
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,000.00 11/30/2025 Non-covered Recipient Entity
PACT-CENTER FOR RESEARCH, PLLC
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185542714
Principal investigator 1 GlaxoSmithKline, LLC. $18,713.70 11/25/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192146179
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,200.00 11/14/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES, PA
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185542718
Principal investigator 1 Genentech, Inc. $30,622.00 11/03/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639445
Principal investigator 1 PFIZER INC. $143.30 10/24/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA RESEARCH
AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD No dispute reported 06/30/2026 1228823592
Principal investigator 1 SANOFI US SERVICES INC. $11,217.80 10/20/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083499
Principal investigator 1 GlaxoSmithKline, LLC. $9,882.90 10/17/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192146167
Principal investigator 1 GlaxoSmithKline, LLC. $4,904.10 10/02/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192146163
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,008.05 09/24/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES, PA
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185542710
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/17/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR No dispute reported 06/30/2026 1192148729
Principal investigator 1 PFIZER INC. $2,181.60 09/15/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD No dispute reported 06/30/2026 1228823572
Principal investigator 1 SANOFI US SERVICES INC. $4,199.60 09/15/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083475
Principal investigator 1 GlaxoSmithKline, LLC. $8,133.30 09/03/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192146171
Principal investigator 1 GENZYME CORPORATION $360.00 08/18/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125849
Principal investigator 1 SANOFI US SERVICES INC. $4,015.10 08/18/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083464
Principal investigator 1 GlaxoSmithKline, LLC. $15,842.70 08/13/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192146184
Principal investigator 1 GlaxoSmithKline, LLC. $676.00 08/07/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192146188
Principal investigator 1 SANOFI US SERVICES INC. $280.00 07/28/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083446
Principal investigator 1 Genentech, Inc. $2,128.00 07/25/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639438
Principal investigator 1 Genentech, Inc. $24,812.00 07/18/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639442
Principal investigator 1 GlaxoSmithKline, LLC. $171.00 07/16/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192146192
Principal investigator 1 GENZYME CORPORATION $1,650.00 07/14/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125837
Principal investigator 1 SANOFI US SERVICES INC. $5,982.00 07/14/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083425
Principal investigator 1 GlaxoSmithKline, LLC. $38,220.30 07/09/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192146175
Principal investigator 1 United Therapeutics Corporation $3,927.68 07/04/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387195
Principal investigator 1 GENZYME CORPORATION $210.00 07/02/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125812
Principal investigator 1 GENZYME CORPORATION $360.00 07/02/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125841
Principal investigator 1 SANOFI US SERVICES INC. $2,180.40 06/23/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083441
Principal investigator 1 SANOFI US SERVICES INC. $6,800.00 06/23/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226125809
Principal investigator 1 SANOFI US SERVICES INC. $2,738.90 06/09/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083398
Principal investigator 1 SANOFI US SERVICES INC. $3,250.00 06/09/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226125800
Principal investigator 1 GENZYME CORPORATION $360.00 05/27/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125784
Principal investigator 1 GENZYME CORPORATION $2,374.00 05/12/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125788
Principal investigator 1 United Therapeutics Corporation $2,000.00 05/08/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387189
Principal investigator 1 United Therapeutics Corporation $2,395.00 05/08/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387193
Principal investigator 1 United Therapeutics Corporation $4,000.00 05/08/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387197
Principal investigator 1 United Therapeutics Corporation $4,790.00 05/08/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387201
Principal investigator 1 United Therapeutics Corporation $6,200.00 05/08/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387203
Principal investigator 1 United Therapeutics Corporation $6,200.00 05/08/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387205
Principal investigator 1 Genentech, Inc. $28,630.00 05/07/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639430
Principal investigator 1 Genentech, Inc. $7,511.00 05/07/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211639433
Principal investigator 1 SANOFI US SERVICES INC. $80.00 04/14/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083380
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,389.98 04/09/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185542716
Principal investigator 1 United Therapeutics Corporation $1,568.49 04/04/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387187
Principal investigator 1 SANOFI US SERVICES INC. $3,790.50 04/02/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083364
Principal investigator 1 GENZYME CORPORATION $360.00 03/24/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125772
Principal investigator 1 SANOFI US SERVICES INC. $14,388.90 03/17/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083360
Principal investigator 1 GENZYME CORPORATION $315.00 03/10/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125907
Principal investigator 1 United Therapeutics Corporation $4,000.00 02/25/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387199
Principal investigator 1 Genentech, Inc. $14,902.00 02/19/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639421
Principal investigator 1 GENZYME CORPORATION $360.00 02/18/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125756
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 02/10/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226125898
Principal investigator 1 Genentech, Inc. $14,456.00 02/07/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211639415
Principal investigator 1 Genentech, Inc. $6,450.00 02/07/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES PA
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639427
Principal investigator 1 GENZYME CORPORATION $1,200.00 02/04/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125903
Principal investigator 1 GENZYME CORPORATION $1,830.00 02/04/2025 Non-covered Recipient Entity
Pulmonary Associates Pa
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125915
Principal investigator 1 SANOFI US SERVICES INC. $239.90 02/04/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083345
Principal investigator 1 AstraZeneca Pharmaceuticals LP $155,927.28 01/17/2025 Non-covered Recipient Entity
PULMONARY ASSOCIATES, PA
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185542712
Principal investigator 1 SANOFI US SERVICES INC. $4,352.50 01/13/2025 Non-covered Recipient Entity
Pact Center For Research Pllc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226083320
Principal investigator 1 United Therapeutics Corporation $10,992.34 01/09/2025 Non-covered Recipient Entity
PACT- Center For Research, PLLC
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387207